Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients
First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects
Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST
Verona Pharma will host an investment community conference call at 8:30 a.m. EDT / 1:30 p.m. BST on Thursday, June 27, 2024 to discuss the US approval of Ohtuvayre. To participate, please dial one of the following numbers and ask to join the Verona Pharma call:
- +1-833-816-1396 for callers in the United States
- +1-412-317-0489 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.